CAS: 1029044-16-3; 5-((5-Chloro-1H-Pyrrolo[2,3-B]Pyridin-3-yl)Methyl)-N-((6-(Trifluoromethyl)Pyridin-3-yl)Methyl)Pyridin-2-Amine

该化合物是一种有选择性地针对聚居模拟因子-1受体(CSF-1R)的小型分子性强血清抑制剂,该受体是肿瘤相关巨型显微phage的主要调节器,主要用于治疗无法进行手术的成年人的症状性静脉巨型细胞肿瘤(TGCT).该复合体表明CSF-1R具有高度的特性,最大限度地减少离目标效应和相关毒性.它的口服生物利用率和有利的药用动能剖面可以方便地进行一次日服药.临床研究表明,TGCT病人的肿瘤反应率和症状改善程度相当高.Pexidartinib的行动机制还将它作为其他CSF-1R依赖的病症调查的候选方.

结构式图片

上下游产品

tert-butyl N-[(tert-butoxy)carbonyl]-N-(5-formylpyridin-2-yl)carbamate 5-chloro-1H-pyrrolo[2,3-b]pyridine 23H27ClN4O5C23H27ClN4O5 6-(trifluoromethyl)pyridine-3-carbaldehyde

合成工艺路线路线简述

    📜2-氨基-3-溴-5-氯吡啶置于盐酸,三乙基硅烷,甲基氯化镁,Palladium Diacetate,N,N-二异丙基乙胺,三(邻甲基苯基)磷,三氟乙酸,Potassium Hydroxide体系中,用 四氢呋喃,甲醇,二甲胺,乙腈 用作溶剂,化学反应 120.5H,反应生成培西达替尼
    参考文献:通过串联tsuji-Trost反应和heck偶联探索pexidartinib的探索性工艺开发
    标题:通过串联tsuji-Trost反应和heck偶联探索pexidartinib的探索性工艺开发
    摘要:抽象的 设计并证明了一种新的合成途径来合成csf1R抑制剂pexidartinib.成功合成的关键是串联的tsuji-Trost反应和与钯和银催化结合的heck偶联.通过五个步骤以49%的收率获得最终产物,纯度高达99.2%.廉价和可用的材料和试剂以及易于进行后处理和纯化的操作使该路线更加实用. 设计并证明了一种新的合成途径来合成csf1R抑制剂pexidartinib.成功合成的关键是串联的tsuji-Trost反应和与钯和银催化结合的heck偶联.通过五个步骤以49%的收率获得最终产物,纯度高达99.2%.廉价和可用的材料和试剂以及易于进行后处理和纯化的操作使该路线更加实用.
    Doi:10.1055/s-0037-1612421

    专利信息


    专利号:US-9745298-B2
    优先权日:2015-05-06
    标题:Synthesis of a compound that modulates kinases
    发明人:IBRAHIM PRABHA N; JIN MASAYOSHI; MATSUURA SHINJI
    权利人:PLEXXIKON INC; DAIICHI SANKYO CO LTD
    摘要:The present disclosure provides processes for the preparation of a compound of formula I: n nor a salt thereof, active on the receptor protein kinases c-Kit and/or c-Fms and/or Flt3. The disclosure also provides compounds and processes for the preparation of the compounds that are synthetic intermediates to the compound of formula I.

    专利号:US-2022259212-A1
    优先权日:2019-07-11
    标题:Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase
    发明人:BOSS CHRISTOPH; CREN SYLVAINE; KIMMERLIN THIERRY; LOTZ-JENNE CARINA; POTHIER JULIEN; TIDTEN-LUKSCH NAOMI
    权利人:IDORSIA PHARMACEUTICALS LTD
    摘要:The present invention relates to compounds of Formula (I) inhibiting indoleamine 2,3-dioxygenase (IDO) and/or tryptophan 2,3-dioxygenase (TDO) enzymes. Further, their synthesis and their use as medicaments in the treatment of inter alia cancer is disclosed.

    专利号:US-12390420-B1
    优先权日:2024-10-22
    标题 :Compositions for targeted delivery of therapeutic agents and methods for the synthesis and use thereof
    发明人:EGUCHI MASAKATSU
    权利人:BRYET US INC
    摘要:The present disclosure provides compositions and methods for delivering therapeutic agents to particular tissues or cells in a subject. The composition disclosed herein combines unique properties of porous micro- or nano-particles with host-guest chemistry provided by functionalized silicon particle, offering a versatile approach to addressing the challenges associated with delivering therapeutic agents to target tissues or sites within the body. The present disclosure also provides a method for synthesizing a composition capable of delivering therapeutic agents to particular tissues or cells in a subject.

    专利号:US-2025082766-A1
    优先权日:2022-03-31
    标 题 :Treatment of brain tumors by targeting the cholesterol pathway in astrocyes
    发明人:MAYO LIOR
    权利人:UNIV RAMOT
    摘要:A method of treating a brain tumor in a subject in need thereof is disclosed. The method comprising administering to the subject a therapeutically effective amount of an agent capable of downregulating activity or expression of a component of the lipid synthesis and/or transportation pathways in an astrocyte in the tumor microenvironment and/or a therapeutically effective amount of a molecule which is associated with lipid uptake by the tumor cells or immune cells in the tumor microenvironment, or a polynucleotide encoding same.

    专利号:US-2018305358-A1
    优先权日:2015-05-06
    标 题:Synthesis of a compound that modulates kinases

    专利号:US-10399975-B2
    优先权日:2015-05-06
    标题:Synthesis of a compound that modulates kinases

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Murga-Zamalloa C, Rolland DC, Polk A, Wolfe A, Dewar H, Chowdhury P, Önder Ö, Dewar R, Brown NA, Bailey NG, Inamdar K, Lim MS, Elenitoba-Johnson KSJ, Wilcox RA. Colony-stimulating Factor 1 Receptor (CSF1R) Activates AKT/mTOR Signaling and Promotes T-cell Lymphoma Viability. Clin Cancer Res. 2019 Oct 21. pii: clincanres.1486.2019. doi: 10.1158/1078-0432.CCR-19-1486. [Epub ahead of print] doi: 10.1007/s40265-019-01210-0. Review. doi: 10.1177/1758835919854238. eCollection 2019.
    5: Piawah S, Hyland C, Umetsu SE, Esserman LJ, Rugo HS, Chien AJ. A case report of vanishing bile duct syndrome after exposure to pexidartinib (PLX3397) and paclitaxel. NPJ Breast Cancer. 2019 Jun 14;5:17. doi: 10.1038/s41523-019-0112-z. eCollection 2019.
    6: Tap WD, Gelderblom H, Palmerini E, Desai J, Bauer S, Blay JY, Alcindor T, Ganjoo K, Martín-Broto J, Ryan CW, Thomas DM, Peterfy C, Healey JH, van de Sande M, Gelhorn HL, Shuster DE, Wang Q, Yver A, Hsu HH, Lin PS, Tong-Starksen S, Stacchiotti S, Wagner AJ; ENLIVEN investigators. Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial. Lancet. 2019 Aug 10;394(10197):478-487. doi: 10.1016/S0140-6736(19)30764-0. Epub 2019 Jun 19.

    合成参考文献


    参考文献:10.1093/neuonc/nov245
    摘要:Butowski N, Colman H, De Groot JF, Omuro AM, Nayak L, Wen PY, Cloughesy TF, Marimuthu A, Haidar S, Perry A, Huse J, Phillips J, West BL, Nolop KB, Hsu HH, Ligon KL, Molinaro AM, Prados M. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. Neuro Oncol. 2016 Apr;18(4):557–64.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知